Sophia A. Mahoney

Sophia A. Mahoney

Auto-generated profile, based on publicly available information

Sophia A. Mahoney

Department of Integrative Physiology University of Colorado Boulder Boulder Colorado USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Hypertension
Verified
Journal Article
Closed access
ZCZachary S Clayton
Zachary S Clayton
MRMatthew J Rossman
Matthew J Rossman
SMSophia A. Mahoney
Sophia A. Mahoney
RVRavinandan Venkatasubramanian
Ravinandan Venkatasubramanian
GMGrace S. Maurer
Grace S. Maurer
DSDouglas R. Seals
Douglas R. Seals
BACKGROUND: Here, we assessed the role of cellular senescence and the senescence associated secretory phenotype (SASP) in age-related aortic stiffening and endothelial dysfunction. METHODS: We studied young (6-8 mo) and old (27-29 mo) p16-3MR mice, which allows for genetic-based clearance of senescent cells with ganciclovir (GCV). We also treated old C57BL/6N mice with the senolytic ABT-263. RESULTS: In old mice, GCV reduced aortic stiffness assessed by aortic pulse wave velocity (PWV; 477±10 vs. 382±7 cm/s, P <0.05) to young levels (old-GCV vs. young-vehicle, P =0.35); ABT-263 also reduced aortic PWV in old mice (446±9 to 356±11 cm/s, P <0.05). Aortic adventitial collagen was reduced by GCV ( P <0.05) and ABT-263 ( P =0.12) in old mice. To show an effect of the circulating SASP, we demonstrated that plasma exposure from Old-vehicle p16-3MR mice, but not from Old-GCV mice, induced aortic stiffening assessed ex vivo (elastic modulus; P <0.05). Plasma proteomics implicated glycolysis in circulating SASP-mediated aortic stiffening. In old p16-3MR mice, GCV increased endothelial function assessed via peak carotid artery endothelium-dependent dilation (EDD; Old-GCV, 94±1% vs. Old-vehicle, 84±2%, P <0.05) to young levels (Old-GCV vs. young-vehicle, P =0.98), and EDD was higher in old C57BL/6N mice treated with ABT-263 vs. vehicle (96±1% vs. 82±3%, P <0.05). Improvements in endothelial function were mediated by increased nitric oxide (NO) bioavailability ( P <0.05) and reduced oxidative stress ( P <0.05). Circulating SASP factors related to NO signaling were associated with greater NO-mediated EDD following senescent cell clearance. CONCLUSIONS: Cellular senescence and the SASP contribute to vascular aging and senolytics hold promise for improving age-related vascular function.

28 May 2025 in Aging Cell
Verified
Journal Article
Open access
KMKevin O. Murray
Kevin O. Murray
SMSophia A. Mahoney
Sophia A. Mahoney
KLKatelyn R. Ludwig
Katelyn R. Ludwig
JMJill H. Miyamoto‐Ditmon
Jill H. Miyamoto‐Ditmon
NVNicholas S. VanDongen
Nicholas S. VanDongen
ZCZachary S Clayton
Zachary S Clayton
Excess cellular senescence contributes to age‐related increases in frailty and reductions in skeletal muscle strength. In the present study, we determined the efficacy of oral intermittent treatment (1 week on—2 weeks off—1 week on) with the natural flavonoid senolytic fisetin to improve frailty and grip strength in old mice. Further, the effects of fisetin on physical function were evaluated in young mice. We performed bulk RNA sequencing of quadricep skeletal muscle to determine the cell senescence‐related signaling pathways modulated by fisetin. We also assessed the relative effects of fisetin on frailty and grip strength with aging in comparison with two other well‐established approaches for the removal of senescent cells: (1) genetic‐based clearance of excess senescent cells in old p16‐3MR mice, a model that allows for clearance of p16‐positive (p16+) senescent cells, and (2) oral intermittent treatment with the synthetic pharmacological senolytic ABT‐263 in old mice. We found that fisetin mitigated the adverse changes in frailty and grip strength with aging. Fisetin had no effects in young mice. The improvements in frailty and grip strength in old mice were accompanied by favorable modulation of the skeletal muscle transcriptome, including lower abundance of cellular senescence‐related genes (e.g., Cdkn1a and Ddit4). Improvements in frailty and grip strength with fisetin were comparable to those observed with genetic‐based clearance of excess p16+ senescent cells and treatment with ABT‐263. Taken together, our findings provide proof‐of‐concept support for fisetin as a senolytic strategy to improve physical function with aging.

1 June 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
ALAbigail G. Longtine
Abigail G. Longtine
RVRavinandan Venkatasubramanian
Ravinandan Venkatasubramanian
MZMelanie C. Zigler
Melanie C. Zigler
ALAlexandra J. Lindquist
Alexandra J. Lindquist
SMSophia A. Mahoney
Sophia A. Mahoney
ZCZachary S Clayton
Zachary S Clayton
Our study demonstrates that with aging, female C57BL/6N mice exhibit higher in vivo aortic stiffness, reduced modulus of elasticity, aortic wall structural and extracellular matrix remodeling, and elevations in systemic inflammation. These changes are largely reflective of those that occur with aging in women. Thus, female C57BL/6N mice are a viable model of human aortic aging and the utility of these animals should be considered in future biomedical investigations.

20 March 2025 in The Journal of Cardiovascular Aging
Verified
Journal Article
Open access
PDF file
SMSophia A. Mahoney
Sophia A. Mahoney
SBSamuel I. Bloom
Samuel I. Bloom
DSDouglas R. Seals
Douglas R. Seals
ADAnthony J. Donato
Anthony J. Donato
MRMatthew J Rossman
Matthew J Rossman
ZCZachary S Clayton
Zachary S Clayton
Cardiovascular diseases (CVD) remain the leading cause of death worldwide, with advancing age being the primary, nonmodifiable risk factor. Vascular dysfunction, namely arterial stiffening and endothelial dysfunction, is the key antecedent to the development of clinical CVD with aging. Fundamental aging macro-mechanistic processes that drive vascular aging include excess oxidative stress, chronic inflammation, and declines in the vasodilatory molecule nitric oxide. An important hallmark of aging that contributes to the vascular aging processes is cellular senescence - a stress response characterized by cell cycle arrest and accompanied by the production and secretion of proinflammatory molecules (i.e., the senescence-associated secretory phenotype [SASP]). Excess senescent cells and the SASP have deleterious effects on vascular function and in states of CVD, making it a putative therapeutic target for improving vascular function and preventing or reversing CVD. This review will focus on the role of cellular senescence in age-related vascular dysfunction and CVD. We will examine established and emerging mechanisms underlying cellular senescence-induced vascular dysfunction. We will then discuss groups with impaired vascular function and high cellular senescence burden and examine strategies to reduce or remove excess senescent cells and the SASP in the groups who are likely to benefit most from these therapies. Finally, we will highlight the systemic effects of vascular senescent cell suppression on other tissues and organs, given the integrative role of the vasculature in physiology. Together, this review will underscore the imperative role of cellular senescence in vascular dysfunction and the need for a deeper understanding of the translational use of cellular senescence and SASP targeting therapies in groups with high senescent cell burden.

1 December 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
RVRavinandan Venkatasubramanian
Ravinandan Venkatasubramanian
SMSophia A. Mahoney
Sophia A. Mahoney
DHDavid A. Hutton
David A. Hutton
NVNicholas S. VanDongen
Nicholas S. VanDongen
VBVienna E. Brunt
Vienna E. Brunt
ZCZachary S Clayton
Zachary S Clayton
We demonstrate that cellular senescence contributes to doxorubicin-related vascular endothelial dysfunction and establishes efficacy for the use of senolytic therapy to improve vascular function following doxorubicin administration. Mechanistically, we found that cellular senescence reduced NO bioavailability and promoted excessive production of vascular mitochondrial superoxide-related oxidative stress, both of which were prevented with senolytic therapy. We translated these findings to humans and showed that ex vivo exposure to doxorubicin impaired arteriole endothelial function, which was prevented with senolytic exposure.

22 April 2026 in Aging Cell
Verified
Journal Article
Open access
SMSophia A. Mahoney
Sophia A. Mahoney
KMKrystyna Mazan‐Mamczarz
Krystyna Mazan‐Mamczarz
DTDimitrios Tsitsipatis
Dimitrios Tsitsipatis
NVNicholas S. VanDongen
Nicholas S. VanDongen
CHCharnae’ Henry‐Smith
Charnae’ Henry‐Smith
ZCZachary S Clayton
Zachary S Clayton
Advancing age is the strongest risk factor for cardiovascular diseases (CVDs), primarily due to progressive vascular endothelial dysfunction. Cellular senescence and the senescence‐associated secretory phenotype (SASP) contribute to age‐related endothelial dysfunction by promoting mitochondrial oxidative stress and inflammation, which reduce nitric oxide (NO) bioavailability. However, the molecular changes in senescent endothelial cells (ECs) and their role in endothelial dysfunction with aging remain unclear. As such, we sought to identify the EC‐related signaling pathways, endothelial‐associated SASP factors, and their impact on endothelial function with aging. Single‐cell transcriptomics was performed on aortas from young (6mos) and old (27mos) female and male mice with and without in vivo senolytic treatment with fisetin (100 mg/kg/day administered intermittently) to characterize EC senescence and transcript expression changes. Circulating levels of SASP factors were measured to assess systemic changes associated with aging and fisetin treatment. Plasma exposure experiments were conducted in isolated mouse arteries and cultured human aortic ECs to determine the causal role of the circulating SASP milieu and specific SASP factors in mediating endothelial dysfunction and underlying mechanisms of action. Senescent ECs exhibited elevated expression of SASP factors, particularly Cxcl12 , which was reversed by fisetin supplementation, with responses also reflected in circulating CXCL12 concentrations. Plasma from old mice impaired endothelial function by inducing vascular cell senescence, reducing NO, increasing mitochondrial oxidative stress, shifting receptor and promoting endothelial‐to‐mesenchymal transition—effects partially driven by CXCL12 and prevented by fisetin. These results identify the SASP and CXCL12 as drivers of age‐related endothelial dysfunction and establish mechanisms of senolytic intervention with fisetin supplementation.